Chemistry:Escaline
Names | |
---|---|
Preferred IUPAC name
2-(4-Ethoxy-3,5-dimethoxyphenyl)ethan-1-amine | |
Other names
3,5-Dimethoxy-4-ethoxy-phenethylamine
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C12H19NO3 | |
Molar mass | 225.28 g/mol |
Melting point | 165 to 166 °C (329 to 331 °F; 438 to 439 K) (hydrochloride) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Escaline (3,5-methoxy-4-ethoxyphenethylamine) is a psychedelic drug and entheogen of the phenethylamine class of compounds. Escaline was first synthesized and reported in the scientific literature by Benington, et al., in 1954, but was later re-examined in the laboratory of David E. Nichols, who prepared a series of mescaline analogues that included escaline, proscaline, and isoproscaline. The effects of this and related mescaline analogues in humans were first described by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin lists the dosage range as 40 to 60 mg of hydrochloride salt, consumed orally.[1] The duration of action was stated to be 8–12 hours.
Escaline is the phenethylamine analog of 3C-E and the 4-ethoxy analog of mescaline.
Legal status
Escaline is illegal in Sweden as of 26 January 2016.[2]
Escaline is a Schedule I controlled substance (DEA #7930) in the United States as it is a positional isomer of TMA (3,4,5-trimethoxyamphetamine).[3]
References
- ↑ PiHKAL entry
- ↑ "31 nya ämnen kan klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. November 2015. http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/november/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/.
- ↑ "Error: no
|title=
specified when using {{Cite web}}". https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf.
See also
Original source: https://en.wikipedia.org/wiki/Escaline.
Read more |